Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Acquires Rapigene For Its SNP Analysis Tools



ENLO, Netherlands--Qiagen announced last week that it has acquired Rapigene, a maker of genomic and single-nucleotide polymorphism analysis technologies. Rapigene was a wholly owned subsidiary of Celltech Group of Bothell, Wash. The agreement called for Qiagen to issue 154,000 shares of its common stock, valued at $12 million, in exchange for 100 percent of outstanding equity in Rapigene.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.